Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definitive radiotherapy with FOLFOX for unresectable esophageal cancer
jRCTs031220219Phase 1Active, not recruiting
- Start
- Oct 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in esophageal cancer. Primary endpoint: Dose-limiting toxicity incidence. Started Oct 2023; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs031220219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220219.